BR112017027332A2 - composições tópicas que compreendem um corticosteróide e um retinóide para tratar psoríase. - Google Patents

composições tópicas que compreendem um corticosteróide e um retinóide para tratar psoríase.

Info

Publication number
BR112017027332A2
BR112017027332A2 BR112017027332-2A BR112017027332A BR112017027332A2 BR 112017027332 A2 BR112017027332 A2 BR 112017027332A2 BR 112017027332 A BR112017027332 A BR 112017027332A BR 112017027332 A2 BR112017027332 A2 BR 112017027332A2
Authority
BR
Brazil
Prior art keywords
retinoid
corticosteroid
topical compositions
treating psoriasis
psoriasis
Prior art date
Application number
BR112017027332-2A
Other languages
English (en)
Other versions
BR112017027332B1 (pt
Inventor
J. Dow Gordon
Pillai Radhakrishnan
Bhatt Varsha
Original Assignee
Valeant Pharmaceuticals North America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56131662&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017027332(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Valeant Pharmaceuticals North America filed Critical Valeant Pharmaceuticals North America
Publication of BR112017027332A2 publication Critical patent/BR112017027332A2/pt
Publication of BR112017027332B1 publication Critical patent/BR112017027332B1/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
BR112017027332-2A 2015-06-18 2016-06-06 Composição farmacêutica tópica para tratar psoríase e seu uso BR112017027332B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562181481P 2015-06-18 2015-06-18
US62/181,481 2015-06-18
PCT/US2016/035991 WO2016205001A1 (en) 2015-06-18 2016-06-06 Topical compositions comprising a corticosteroid and a retinoid for treating psoriasis

Publications (2)

Publication Number Publication Date
BR112017027332A2 true BR112017027332A2 (pt) 2018-09-04
BR112017027332B1 BR112017027332B1 (pt) 2023-11-07

Family

ID=56131662

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017027332-2A BR112017027332B1 (pt) 2015-06-18 2016-06-06 Composição farmacêutica tópica para tratar psoríase e seu uso

Country Status (20)

Country Link
US (7) US10251895B2 (pt)
EP (1) EP3310389B1 (pt)
JP (1) JP6997624B2 (pt)
KR (2) KR20240035898A (pt)
CN (1) CN108282998B (pt)
AU (1) AU2016279801B2 (pt)
BR (1) BR112017027332B1 (pt)
CA (1) CA2988577A1 (pt)
CY (1) CY1123354T1 (pt)
DK (1) DK3310389T3 (pt)
ES (1) ES2812451T3 (pt)
HR (1) HRP20201250T1 (pt)
HU (1) HUE050603T2 (pt)
LT (1) LT3310389T (pt)
MX (1) MX2017015990A (pt)
PL (1) PL3310389T3 (pt)
PT (1) PT3310389T (pt)
RS (1) RS60672B1 (pt)
SI (1) SI3310389T1 (pt)
WO (1) WO2016205001A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6997624B2 (ja) 2015-06-18 2022-01-17 ボシュ ヘルス ユーエス,エルエルシー. 乾癬を治療するためのコルチコステロイドおよびレチノイドを含む局所用組成物
CN108024954A (zh) * 2015-07-13 2018-05-11 瑞迪博士实验室有限公司 局部用类视黄醇组合物
JP7410720B2 (ja) * 2017-05-12 2024-01-10 ボシュ ヘルス アイルランド リミテッド 皮膚疾患を治療するための局所組成物および方法
US11311482B2 (en) * 2017-05-12 2022-04-26 Bausch Health Us, Llc Topical compositions and methods for treating skin diseases
ES2875851T3 (es) * 2017-06-23 2021-11-11 Salvat Lab Sa Una composición de nanoemulsión de clobetasol de aceite en agua
US10653656B2 (en) 2018-04-05 2020-05-19 Bausch Health Ireland Limited Topical pharmaceutical compositions for treating skin conditions
EP3775116A4 (en) * 2018-04-05 2022-03-23 Bausch Health Ireland Limited POLYMER EMULSION DISTRIBUTION SYSTEMS
EP3937905A4 (en) * 2019-03-14 2022-12-28 Crescita Therapeutics Inc. FLUSHABLE COMPOSITIONS AND THEIR USES FOR DELIVERY
KR102327827B1 (ko) 2019-11-01 2021-11-18 한국과학기술연구원 강황 추출물을 유효성분으로 포함하고 자외선 처리를 포함하는 건선 개선용 조성물
KR102451304B1 (ko) 2020-09-14 2022-10-07 한국과학기술연구원 꿩의다리속 추출물을 유효성분으로 포함하는 건선 개선용 조성물
KR102527907B1 (ko) 2020-09-14 2023-05-03 한국과학기술연구원 무산상자 추출물을 유효성분으로 포함하는 건선 개선용 조성물
KR102461001B1 (ko) 2020-09-14 2022-11-01 한국과학기술연구원 술패랭이꽃 추출물을 유효성분으로 포함하는 건선 개선용 조성물
KR20230041257A (ko) 2021-09-17 2023-03-24 한국과학기술연구원 시미시푸고라이드 에이를 유효성분으로 포함하는 건선 개선용 조성물
KR20230041255A (ko) 2021-09-17 2023-03-24 한국과학기술연구원 눈개승마 추출물을 유효성분으로 포함하는 건선 개선용 조성물
CN113975249B (zh) * 2021-10-14 2023-01-03 中山大学·深圳 Tris-BNP纳米颗粒的制备及其在皮肤疾病治疗中的应用
CN113712918A (zh) * 2021-10-28 2021-11-30 济南纽华医药科技有限公司 一种阿普斯特微乳及其制备方法

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU75903A1 (pt) 1976-09-29 1978-05-16
NL7105591A (en) 1971-04-24 1972-10-26 Topical antiphlogistic compsns - contng 3, 20-diketo-9 alpha, 11 beta-dichloro - 16 alpha, 17 alpha-dimethyl-21-hydroxy pregna-1,4-
DE2655570A1 (de) 1975-12-12 1977-06-16 Ciba Geigy Ag Neue polyhalogensteroide und verfahren zu ihrer herstellung
US4048310A (en) 1976-02-24 1977-09-13 E. R. Squibb & Sons, Inc. Topical steroid formulation in form of lotion or cream
US4083974A (en) 1977-03-07 1978-04-11 The Upjohn Company Topical steroidal anti-inflammatory preparations containing polyoxypropylene 15 stearyl ether
JPS5850964B2 (ja) 1978-03-07 1983-11-14 東興薬品工業株式会社 ステロイド含有クリ−ム製剤およびその製造方法
US4299828A (en) 1979-05-31 1981-11-10 E. R. Squibb & Sons, Inc. Corticosteroid stick formulations
US4233295A (en) 1979-05-31 1980-11-11 E. R. Squibb & Sons, Inc. Corticosteroid formulations containing sebacate carrier
AU5794680A (en) 1979-05-31 1980-12-04 E.R. Squibb & Sons, Inc. Corticosteroid stick formulations
CH649923A5 (de) 1980-10-06 1985-06-28 Glaxo Group Ltd Topisch verabreichbare pharmazeutische zusammensetzungen, enthaltend anti-inflammatorische steroide.
JPS58225009A (ja) 1982-06-23 1983-12-27 Shionogi & Co Ltd コルチコステロイド外用製剤
DE3225848A1 (de) 1982-07-07 1984-01-19 Schering AG, 1000 Berlin und 4709 Bergkamen Kortikoidhaltige zubereitung zur topischen applikation
GB8401965D0 (en) 1984-01-25 1984-02-29 Beecham Group Plc Composition
CA1303991C (en) 1986-03-31 1992-06-23 Chung H. Cheng Composition and method for delivering a steroid active ingredient
US5019569A (en) 1986-11-03 1991-05-28 Ortho Pharmaceutical Corporation Reversal of glucocorticoid-induced skin atrophy
JPH0676327B2 (ja) 1987-04-14 1994-09-28 株式会社大塚製薬工場 ステロイド軟膏製剤
JPH0676328B2 (ja) 1987-04-14 1994-09-28 株式会社大塚製薬工場 ステロイドクリ−ム製剤
JPH07116026B2 (ja) 1987-07-07 1995-12-13 株式会社資生堂 ジクロフェナックナトリウム含有乳化外用剤
US5422361A (en) 1989-12-20 1995-06-06 Schering Corporation Stable cream and lotion bases for lipophilic drug compositions
JP3340126B2 (ja) 1990-03-02 2002-11-05 株式会社資生堂 非ステロイド系消炎鎮痛薬を含む水中油型乳化組成物
TW218849B (pt) * 1991-05-17 1994-01-11 Bristol Myers Squibb Co
US5326566A (en) 1991-05-17 1994-07-05 Bristol-Myers Squibb Company Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
EP0969847A1 (en) 1997-02-20 2000-01-12 Allergan Sales, Inc. Tazarotene and corticosteroid treatment for psoriasis
SE9800729L (sv) 1998-03-06 1999-09-07 Scotia Lipidteknik Ab Ny topikal formulering I
GB9823036D0 (en) 1998-10-22 1998-12-16 Glaxo Group Ltd Fluticasone lotion having improved vasoconstrictor activity
WO2000047211A1 (en) * 1999-02-12 2000-08-17 Susan Bershad Short contact treatment of psoriasis with topical retinoids
US6730308B1 (en) * 1999-03-08 2004-05-04 Allergan, Inc. Tazarotene and alpha hydroxy acid treatment for psoriasis and/or photodamage
US6479058B1 (en) 1999-09-02 2002-11-12 Mccadden Michael E. Composition for the topical treatment of poison ivy and other forms of contact dermatitis
US6656928B1 (en) 1999-09-02 2003-12-02 Mccadden Michael E. Composition for the topical treatment of rashes, dermatoses and lesions
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
ES2298264T3 (es) * 2000-10-27 2008-05-16 Leo Pharma A/S Composicion topica que contiene al menos una vitamina d o un analogo de vitamina d y al menos un corticoesteroide.
US6709663B2 (en) 2001-08-31 2004-03-23 Healthpoint, Ltd. Multivesicular emulsion drug delivery systems
US6765001B2 (en) 2001-12-21 2004-07-20 Medicis Pharmaceutical Corporation Compositions and methods for enhancing corticosteroid delivery
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US7544674B2 (en) 2002-10-25 2009-06-09 Galderma S.A. Topical skin care composition
CN1210034C (zh) * 2002-12-06 2005-07-13 重庆华邦制药股份有限公司 治疗银屑病的药物组合物
US20040176337A1 (en) 2002-12-31 2004-09-09 Wockhardt Limited Benzoquinolizine-2-carboxylic acid-containing compositions
JP2004359585A (ja) 2003-06-03 2004-12-24 Medorekkusu:Kk 被膜形成型の副腎皮質ステロイド薬含有外用製剤
CN1210035C (zh) * 2003-09-29 2005-07-13 中国医学科学院皮肤病研究所 治疗银屑病的复方外用药物
CN1210041C (zh) * 2003-09-29 2005-07-13 中国医学科学院皮肤病研究所 治疗痤疮的复方外用药物
US8741333B2 (en) 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for treating dermatitis or psoriasis
WO2006098353A1 (ja) 2005-03-15 2006-09-21 Kyowa Hakko Kogyo Co., Ltd. 外用剤
TW200740441A (en) * 2005-06-17 2007-11-01 Combinatorx Inc Methods and reagents for the treatment of inflammatory disorders
CA2633464A1 (en) 2005-12-14 2007-09-07 Zars Pharma, Inc. Compositions and methods for dermal delivery of drugs
DK2494959T3 (en) 2006-07-05 2015-02-23 Foamix Pharmaceuticals Ltd Foam Bart dicarboxylsyrebærestof and pharmaceutical compositions thereof
EP2097065A2 (en) 2006-11-29 2009-09-09 Foamix Ltd. Foamable waterless compositions with modulating agents
RU2470645C2 (ru) 2007-09-10 2012-12-27 Гленмарк Фармасьютикалс Лимитед Фармацевтическая композиция для местного применения, содержащая комбинацию фузидовой кислоты и кортикостероида
WO2009084020A2 (en) 2007-10-18 2009-07-09 Glenmark Pharmaceuticals Limited Topical composition comprising halobetasol and salicylic acid
WO2009158687A1 (en) 2008-06-26 2009-12-30 Anterios, Inc. Dermal delivery
US10568859B2 (en) 2009-02-25 2020-02-25 Mayne Pharma Llc Topical foam composition
US20130310355A1 (en) 2009-12-15 2013-11-21 Young Pharmaceuticals, Inc. Low toxicity topical active agent delivery system
WO2012051614A2 (en) 2010-10-15 2012-04-19 Kulesza John E Delivery of hydrophobic bioactive agents
CA2816872C (en) * 2010-11-04 2019-02-12 442 Ventures, Llc Composition and method for treating skin conditions
US8809307B2 (en) * 2010-11-22 2014-08-19 Dow Pharmaceutical Sciences, Inc. Pharmaceutical formulations containing corticosteroids for topical administration
US9034926B2 (en) * 2010-12-30 2015-05-19 Nicholas V. Perricone Topical nitrone spin trap compositions for psoriasis
US20120328670A1 (en) 2011-06-03 2012-12-27 Allergan, Inc. Targeted Delivery of Retinoid Compounds to the Sebaceous Glands
SG11201403762PA (en) * 2012-01-09 2014-07-30 Almirall Sa Topical pharmaceutical compositions comprising bexarotene and a corticosteroids
US20140112959A1 (en) 2012-10-18 2014-04-24 MiCal Pharmaceuticals LLC - H Series, a Series of MiCal Pharmaceuticals LLC, a Multi-Division Limite Topical steroid composition and method
CN104288157B (zh) * 2013-01-29 2018-04-13 江苏知原药业有限公司 包含丙酸氯倍他索和维a酸的固体分散体及其制备方法
WO2015044857A1 (en) * 2013-09-25 2015-04-02 Ranbaxy Laboratories Limited Topical spray composition of halobetasol
US20190133943A1 (en) 2015-06-18 2019-05-09 Valeant Pharmaceuticals North America Topical compositions and methods for treating skin diseases
JP6997624B2 (ja) 2015-06-18 2022-01-17 ボシュ ヘルス ユーエス,エルエルシー. 乾癬を治療するためのコルチコステロイドおよびレチノイドを含む局所用組成物
US11311482B2 (en) 2017-05-12 2022-04-26 Bausch Health Us, Llc Topical compositions and methods for treating skin diseases
JP7410720B2 (ja) 2017-05-12 2024-01-10 ボシュ ヘルス アイルランド リミテッド 皮膚疾患を治療するための局所組成物および方法

Also Published As

Publication number Publication date
US10426787B2 (en) 2019-10-01
AU2016279801B2 (en) 2021-09-09
AU2016279801A1 (en) 2018-01-04
KR20180053292A (ko) 2018-05-21
LT3310389T (lt) 2020-11-10
CY1123354T1 (el) 2021-12-31
US10251895B2 (en) 2019-04-09
KR102643849B1 (ko) 2024-03-07
ES2812451T3 (es) 2021-03-17
PT3310389T (pt) 2020-11-11
CA2988577A1 (en) 2016-12-22
CN108282998A (zh) 2018-07-13
US20160367570A1 (en) 2016-12-22
JP2018526325A (ja) 2018-09-13
KR20240035898A (ko) 2024-03-18
CN108282998B (zh) 2021-07-06
DK3310389T3 (da) 2020-08-10
RS60672B1 (sr) 2020-09-30
PL3310389T3 (pl) 2020-11-30
BR112017027332B1 (pt) 2023-11-07
US20210330681A1 (en) 2021-10-28
US20230355640A1 (en) 2023-11-09
HUE050603T2 (hu) 2020-12-28
EP3310389A1 (en) 2018-04-25
SI3310389T1 (sl) 2020-11-30
EP3310389B1 (en) 2020-07-01
US20180177803A1 (en) 2018-06-28
WO2016205001A1 (en) 2016-12-22
US11679115B2 (en) 2023-06-20
US11679116B2 (en) 2023-06-20
US20230086282A1 (en) 2023-03-23
US20210145847A1 (en) 2021-05-20
US11648256B2 (en) 2023-05-16
MX2017015990A (es) 2018-11-09
US20190231797A1 (en) 2019-08-01
HRP20201250T1 (hr) 2020-11-13
JP6997624B2 (ja) 2022-01-17

Similar Documents

Publication Publication Date Title
BR112017027332A2 (pt) composições tópicas que compreendem um corticosteróide e um retinóide para tratar psoríase.
DK3258942T3 (da) Kosmetiske og topiske sammensætninger omfattende cannabigerol og cannabidiol
BR112018001190A2 (pt) composições úteis para tratar distúrbios relacionados a kit e pdfgr
DK3782996T3 (da) NRF2-regulatorer
BR112017013320A2 (pt) composições inibidoras de corrosão para tratamentos de acidificação
ZA201800080B (en) Topical retinoid compositions
CL2018003443A1 (es) Tratamientos para el cancer.
BR112017019352A2 (pt) composições tópicas comprimidas a corticosteróide aplicações relacionadas
CL2019001760A1 (es) Composiciones que comprenden ácido acético y ácido hipoclórico y métodos para tratar una biopelícula.
BR112015023273A2 (pt) método para programar a ovulação.
DK3349752T3 (da) Aza-adamantan sammensætning til sårheling
BR112018002283A2 (pt) Composição para administração tópica a um sujeito, e, formulação tópica
DK3324938T3 (da) Topikale formuleringer og behandlinger
IL246800A0 (en) Local antifungal preparation for the treatment of nail fungus
BR112017016048A2 (pt) método e agente anti-inflamatório
TR201512960A1 (tr) Topi̇kal formülasyonlar
ES1135628Y (es) Monoboya para vertido controlado
CL2018000985A1 (es) Composición y método para tratar sustratos.
CL2017002884A1 (es) Tratamientos para el cancer
MA42111A (fr) Compositions pharmaceutiques topiques
DK3349722T3 (da) Topisk hirsutisme-behandling
ES1166908Y (es) Apósito para pomada
ES1173908Y (es) Estructura para cinta de correr
ES1149333Y (es) Fondo para expositores de joyeria
TH1501004914A (th) องค์ประกอบทางผิวหนังวิทยาต้านจุลชีพแบบทา

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15V Prolongation of time limit allowed

Free format text: DE ACORDO COM COMUNICADO PUBLICADO NA RPI 2526 DE 04/06/2019 FICAM DEVOLVIDOS DE 11/06/2019 ATE 14/06/2019 OS PRAZOS VENCIDOS NAS DATAS DIVULGADAS DENTRO DO COMUNICADO.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/06/2016, OBSERVADAS AS CONDICOES LEGAIS